NASDAQ: BIOA · Life Sciences · 3 alerts · CIK 1709941
Share price
$5.22Close, Nov 16
Market cap
$240M
Shares outstanding
45.96MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All BioAge Labs, Inc. filings on SEC EDGAR ↗
BioAge Labs reported a net loss of $81.9 million for the nine months ended September 30, 2026, compared to $54.7 million for the same period in 2025, driven primarily by a significant increase in research and development expenses. The company strengthened its balance sheet through an underwritten stock offering and at-the-market sales, ending the period with $352.3 million in cash, cash equivalents, and marketable securities.
BioAge Labs reported third quarter 2026 financial results, highlighting the dosing of the first participant in its Phase 2 QUELL-DME trial for diabetic macular edema. The company also completed enrollment in its Phase 2 QUELL-CV trial for obesity and inflammation, with topline data expected in Q4 2026.
Term
Q3 2026
“NLRP3 is a key switch that turns on inflammation and drives multiple diseases. Injectable drugs that block two major inflammatory signals, IL-1 and IL-6, are already approved for multiple indications, but a once-daily pill that works earlier in the process—and also lowers IL-18 and reduces harmful inflammatory cell death—could help many more people. That is the opportunity we are pursuing with BGE-102.”
Kristen Fortney, Ph.D., CEO and co-founder of BioAge
BioAge Labs announced the first participant has been dosed in its QUELL-DME Phase 2 clinical trial evaluating BGE-102, an oral NLRP3 inhibitor, for the treatment of diabetic macular edema. The 180-participant trial will evaluate the drug as both a monotherapy and in combination with anti-VEGF therapy, with topline results expected in the second half of 2027.